Advanced search

Instruments

	Name		Stock exchange	Average volume	Price	Type
	WILLIAM PENN BANCORPORATION	WMPN	Nasdaq	10,509	12.18 USD	Stock
	WILLIAM H. SADLIER, INC.	SADL	OTC Markets	0	18.4 USD	Stock

News (61)

Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors	23-07-11	PR
NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	23-05-19	AQ
DARE BIOSCIENCE, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-06-24	AQ
REGULUS THERAPEUTICS INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	22-06-13	AQ
Neurocrine Biosciences : 2021 Annual Report*	22-06-03	PU
NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	22-05-23	AQ
Dare Bioscience : 2021 Proxy Statement	21-07-08	PU
REGULUS THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	21-06-16	AQ
FATE THERAPEUTICS INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	21-06-07	AQ
Transcript : Fate Therapeutics, Inc. - Shareholder/Analyst Call	21-06-02
NEUROCRINE BIOSCIENCES INC : Submission of Matters to a Vote of Security Holders (form 8-K)	21-05-21	AQ
Neurocrine Biosciences : Announces Appointment of Johanna Mercier to Board of Directors	21-04-19	AQ
Neurocrine Biosciences : Announces Appointment of Johanna Mercier to Board of Directors	21-04-16	PR
Dare Bioscience : Current Report (SEC Filing - 8-K)	21-02-16	PU
Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update	20-08-12	GL
REGULUS THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	20-06-19	AQ
NEUROCRINE BIOSCIENCES INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	20-05-21	AQ
Fate Therapeutics Announces Changes to its Board of Directors	20-05-05	GL
Neurocrine Biosciences : Announces Appointment of Shalini Sharp to Board of Directors	20-02-03	PR
REGULUS THERAPEUTICS INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	19-12-26	AQ
Regulus Therapeutics Inc. announced that it has received $42.736888 million in funding from a group of investors	19-12-25	CI
Neurocrine Biosciences : Announces Appointment of Leslie V. Norwalk to Board of Directors	19-09-11	PR
Daré Bioscience, Inc. Announces Board Changes	19-07-15	CI
Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors	19-07-15	GL
Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors	19-07-15	CI
ViaSat : CONNECT to Honor Three Distinguished Innovators at Annual Awards	18-10-22	PU
Transcript : Daré Bioscience, Inc. - Shareholder/Analyst Call	18-07-10
Neurocrine Biosciences : Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego	18-06-08	PR
Daré Bioscience, Inc. Announces Board Changes	17-07-20	CI
Cerulean Pharma : Urges Stockholders to Vote for Proposals at July 19, 2017 Special Stockholder Meeting	17-06-27	BU
Cerulean Pharma : and Daré Announce Awards for Daré CEO	17-05-08	BU
Transcript : Illumina Inc., Q4 2015 Earnings Call, Feb 02, 2016	16-02-02
Illumina Inc. Announces Board Changes	16-02-01	CI
Illumina : Forms New Company to Enable Early Cancer Detection via Blood-Based Screening	16-01-10	BU
Grail announced that it has received $100 million in funding from Arch Venture Partners, L.P., Illumina Inc., Sutter Hill Ventures, Bezos Expeditions, LLC, and other investors.	16-01-09	CI
Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony	15-11-09	GL
Neurocrine Biosciences : Announces the Appointment of George J. Morrow to its Board of Directors	15-09-30	PR
Biogen : Neurocrine Biosciences Announces the Appointment of Dr. Alfred W. Sandrock to its Board of Directors	15-09-03	PR
Corporate Directors Forum : Honors Six San Diego Executives with 2015 Director of The Year Awards	15-07-15	PR
Transcript : Illumina Inc. - Shareholder/Analyst Call	15-05-27
Capital One Financial : Project Update, Awards, Appointment, Product Launch, and Sponsorship - Research Reports on D.R. Horton, Mallinckrodt, Illumina, Ventas and Capital One Financial	14-09-29	PR
Fate Therapeutics, Inc. Announces Board Changes	14-06-11	CI
Regulus Therapeutics Inc. Elects Bruce L.A. Carter, Mark G. Foletta, William Rastetter and Douglas Williams as Directors	13-06-12	CI
Regulus Therapeutics Inc : Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors	13-04-01	PR
Regulus Appoints William H. Rastetter to its Board	13-04-01	CI

12NextSee all

Companies (51)

THE SHERWIN-WILLIAMS COMPANY 79 658 M $

The Sherwin-Williams Company specializes in developing, manufacturing and marketing paints, coating and related products. Net sales break down by activity as follows: - retail sale of paints and industrial and architectural coating (56.5%): owned, at the ...

THE SHERWIN-WILLIAMS COMPANY 79 658 M $

WILLIAMS-SONOMA, INC. 20 378 M $

Williams-Sonoma, Inc. is an omni-channel specialty retailer for home products. Its brands include Williams Sonoma, Pottery Barn, Pottery Barn Kids, Pottery Barn Teen, West Elm, Williams Sonoma Home, Rejuvenation, and Mark and Graham are marketed through e ...

WILLIAMS COMPANIES 49 189 M $

The Williams Companies, Inc. specializes in the production and distribution of natural gas. Net sales break down by activity as follows: - natural gas transportation and storage (77.5%): owned, at the end of 2020, a pipeline network of over 48,280.3 km. ...

AGREE REALTY CORPORATION 6 060 M $

Agree Realty Corporation is an integrated real estate investment trust (REIT) primarily focused on the ownership, acquisition, development and management of retail properties net-leased to tenants. The Company's assets are held by, and all of its operatio ...

THE BERKELEY GROUP HOLDINGS PLC 6 938 M $

The Berkeley Group Holdings plc is a United Kingdom-based company engaged in building homes and neighborhoods across London, Birmingham, and the South of England. The Company and its subsidiaries are engaged in residential-led, mixed-use property developm ...

AGREE REALTY CORPORATION 6 060 M $

THE GPT GROUP 5 340 M $

The GPT Group is an Australia-based vertically integrated diversified property company that owns and actively manages a portfolio of Australian retail, office and logistics assets, with assets under management of approximately $32.2 billion. The Company u ...

THE BERKELEY GROUP HOLDINGS PLC 6 938 M $

VOLATUS CAPITAL CORP. 134 728 $

Volatus Capital Corp. is focused on the exploration and development of resources in gold and the green economy. The Company's main focus are the JD Project, immediately adjacent to Benchmark Metals (BNCH) Lawyers property; the Williams Extension Project, ...

1234Next

Insiders

William Rastetter

Founder of Receptos LLC, Apoptos, Inc. and GRAIL, Inc., William H. Rastetter is an entrepreneur and businessperson who has been at the head of 13 different companies and occupies the position of Chairman of Neurocrine Biosciences, Inc., Chairman for Fate Therapeutics, Inc. and Chairman for Daré Bioscience, Inc. Dr. Rastetter is also on the board of California Institute of Technology, CONNECT, Regulus Therapeutics, Inc. (former Chairman) and GRAIL, Inc. (former Chairman). In his past career Dr. Rastetter was Executive Chairman for Biogen, Inc. Chairman & Chief Executive Officer at IDEC Pharmaceuticals Corp. and Executive Chairman for Biogen Idec, Inc. (North Carolina) (both are subsidiaries of Biogen, Inc.), Chairman of Illumina, Inc., Partner at Venrock Associates, Chairman & Chief Executive Officer for Celgene Corp., Chairman & Chief Executive Officer at Apoptos, Inc., Executive Chairman at Receptos LLC, Chairman for Cerulean Pharma, Inc., Director-Corporate Ventures at Genentech, Inc., Faculty Member at Harvard University and Associate Professor at Massachusetts Institute of Technology. He received a doctorate and a graduate degree from Harvard University and an undergraduate degree from Massachusetts Institute of Technology.

Gerhard J. Rastetter

Rolly Rastetter

Andreas Rastetter

Andreas Rastetter is associated with Autohaus Rastetter GmbH and Rastetter Holding GmbH as a Co-Managing Director.

Pascal Rastetter

Pascal Rastetter worked as a Principal Consultant at POSpulse GmbH in 2016.

Robyn K. Rastetter

Petra Rastetter

Petra Rastetter currently works at Sparkasse Karlsruhe, as Member-Supervisory Board.

Reimund Rastetter

Reimund Rastetter has worked as a Co-Managing Director at Autohaus Rastetter GmbH and Rastetter Holding GmbH.

Bruce Rastetter